ArticleBMC gastroenterology2026
Superior diagnostic yield of mini-laparoscopy over transjugular liver biopsy in acute-on-chronic liver failure: a case-control study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsHepatic failure frequently requires liver biopsy for etiologic classification and delimitation from differential diagnoses to inform treatment decisions. Both mini-laparoscopic (MB) and transjugular liver biopsy (TB) are considered safe diagnostic modalities in liver cirrhosis (LC) patients but may associate with varying success and complication rates. We aimed to characterize the clinical values of MB and TB in patients with LC and particularly acute-on chronic liver failure (ACLF), where clinical acuity and patient risk are high.
methodsIn this retrospective study, we analyzed 73 consecutive adult ACLF patients undergoing liver biopsy (57x ACLF-MB, 16x ACLF-TB) and performed 1:2-matching with non-ACLF LC patients for either biopsy modality to assess technical success, complications, and diagnostic versatility.
resultsBaseline disease severity was comparable between biopsy modalities (MELD score: ACLF-MB 27 [22-33] vs. ACLF-TB 27 [19.75-32], p = 0.640). MB and TB were successfully completed in the large majority (MB 169/171 vs. TB 48/48; p = n.s.) of procedures. While the presence of ACLF associated with a higher rate of minor complications following MB (ACLF-MB: 80.7% vs. LC-MB: 52.6%, p < 0.001), major biopsy-related complications were generally rare, and their occurrence did not differ between biopsy modalities. MB-specimens were technically evaluable in 100% of successfully performed procedures, contrasting 31.3% of technical failures in ACLF-TB and 37.5% in LC-TB (all p < 0.001), respectively. In suitable biopsies, failure to obtain a histological diagnosis was observed in 3.6% of ACLF-MB, 6.2% of ACLF-TB, 17.7% of LC-MB, and 6.2% of LC-TB cases, ultimately resulting in higher rates of established or corrected diagnoses via MB than TB.
conclusionsMB provides higher diagnostic yield than TB at the cost of increased minor complication rates in ACLF. Where locally available and technically feasible, MB may be considered the preferred route of liver biopsy in end-stage chronic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.